MMPW
DFTX

Mitchell McLeod Pugh & Williams’s Definium Therapeutics DFTX Stock Holding History

Mitchell McLeod Pugh & Williams’s Portfolio DFTX Stock Details DFTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-20,000
Closed -$130K – 284
2025
Q2 		$130K Hold
20,000
– – 0.02% 270
2025
Q1 		$117K Hold
20,000
– – 0.02% 266
2024
Q4 		$139K Hold
20,000
– – 0.03% 254
2024
Q3 		$114K Hold
20,000
– – 0.02% 267
2024
Q2 		$144K Hold
20,000
– – 0.03% 260
2024
Q1 		$188K Hold
20,000
– – 0.05% 255
2023
Q4 		$73.2K Buy
+20,000
New +$60.2K 0.02% 253

Other funds holding DFTX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $25.6B AUM 26.83% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Mitchell McLeod Pugh & Williams's DFTX Position: Q3 2025 in Review

Mitchell McLeod Pugh & Williams sold out of Definium Therapeutics (DFTX) in Q3 2025, closing a stake of 20,000 shares — an estimated $130K sold.

Mitchell McLeod Pugh & Williams first reported a position in DFTX in Q4 2023 and held it in 7 quarters. The position peaked at $188K in Q1 2024. 195 funds tracked by Wall St. Rank hold DFTX as of Q3 2025.

  • Mitchell McLeod Pugh & Williams reported no remaining Definium Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Mitchell McLeod Pugh & Williams sold 20,000 Definium Therapeutics shares in Q3 2025, an estimated $130K.
  • Mitchell McLeod Pugh & Williams first reported a position in Definium Therapeutics in Q4 2023 and held it in 7 quarters.
  • Mitchell McLeod Pugh & Williams's Definium Therapeutics position peaked at $188K in Q1 2024.
  • 195 funds tracked by Wall St. Rank held Definium Therapeutics as of Q3 2025.

Based on Mitchell McLeod Pugh & Williams's 13F filing for Q3 2025, filed 30 Oct 2025.